Coronary/Structural Heart

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Patent provides intellectual property protection until December 2040 PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030 There are currently no FDA approved treatments for PH-HFpEF Levosimendan combines two MoAs that, for the first time, specifically target the symptoms PH-HFpEF patients […]

FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol

Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C) 48% reduction in LDL-C from baseline at week 24 when Evkeeza was added to other lipid-lowering therapies in the pivotal trial TARRYTOWN, N.Y., March 22, […]

Nanox.AI Expands Footprint Through New Global Partnership with Ferrum Health

Partnership with Ferrum Health offers unprecedented data security and an integrated AI platform to streamline health systems’ adoption of AI technology, such as Nanox’s Bone solution (HealthOST) and cardiac solution (HealthCCSng) NEVE ILAN, Israel, March 22, 2023 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging […]

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the peer-reviewed publication of an analysis of available ultrafiltration clinical trials with findings that support ultrafiltration as a safe and effective therapeutic option […]

Biometrics Leader LifeQ Revolutionizes Healthcare with Disease Screening and Early Detection

Clinical-grade biometric data flags chronic and acute diseases and disorders—assisting clinicians, improving health and wellness, and bettering lives ATLANTA, March 20, 2023 /PRNewswire/ — LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches […]

MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Genomics Annual Meeting

Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical tool. MENLO PARK, Calif., March 16, 2023 /PRNewswire/ — MyOme, Inc., a clinical whole genome platform analysis company and a leader in the development of polygenic risk scores with […]

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today released the following statement: Since joining the company two weeks […]

New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy

Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy MANSFIELD, Mass., March 15, 2023 /PRNewswire/ — BioVentrix®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed paper in the Journal of Clinical Medicine, […]

Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study

GENEVA, March 15, 2023 /PRNewswire/ — MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus […]